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Background: Alveolar rhabdomyosarcomas (ARMS) can harbour MET/ALK alterations. We 
prospectively assessed crizotinib in patients with advanced/metastatic ARMS. 
 
Methods: Eligible patients with a central diagnosis of ARMS received oral crizotinib 250mg twice 
daily. Patients were attributed to MET/ALK+ or MET/ALK- sub-cohorts by assessing the presence or 
absence of the forkhead box O1 (FOXO1; a marker of MET upregulation) and/or anaplastic 
lymphoma kinase (ALK) gene rearrangement. The primary endpoint was the objective response rate 
(ORR). Secondary endpoints included duration of response (DOR), disease control rate (DCR), 
progression-free survival (PFS), progression-free rate (PFR), overall survival (OS), and safety.  
 
Findings: Nineteen of 20 consenting patients had centrally confirmed ARMS. Molecular 
assessment revealed rearrangement of FOXO1 in 17 tumours, and ALK in none. Thirteen eligible 
patients were treated, but only 8 were evaluable for the primary endpoint due to the observed 
aggressiveness of the disease. Among 7 evaluable MET+/ALK- patients, only one achieved a 
confirmed partial response (ORR: 14.3%; 95% CI: 0.3–57.8) with a DOR of 52 days. Further 
MET+/ALK- efficacy endpoints were: DCR: 14.3% (95% CI: 0.3–57.8), median PFS: 1.3 months 
(95% CI: 0.5–1.5), median OS: 5.6 months (95% CI: 0.7–7.0). The remaining MET+/ALK- and 
MET-/ALK- patients had early progression as best response. Common treatment-related adverse 
events were fatigue (5/13 [38.5%]), nausea (4/13 [30.8%]), anorexia (4/13 [30.8%]), vomiting (2/13 
[15.4%]) and constipation (2/13 [15.4%]). All 13 treated patients died early due to progressive 
disease. 
 
Interpretation:  Crizotinib is well tolerated, but lacks clinically meaningful activity as a single 
agent in patients with advanced metastatic ARMS. Assessing single agents in aggressive, 
chemotherapy-refractory ARMS is challenging and future trials should explore established 
chemotherapy +/- investigational compounds in earlier lines of treatment. 
 
 
Clinical trial number: EORTC 90101, ClinicalTrials.gov NCT01524926 
 





 Chemotherapy-refractory ARMS is a clinically aggressive disease commonly associated 
with FOXO1 rearrangement, but a low incidence of ALK alterations. 
 Crizotinib is well-tolerated, but has limited single-agent activity in chemotherapy-refractory 
ARMS without ALK rearrangement. 









Rhabdomyosarcoma (RMS) is a rare malignancy, however it is the most common sarcoma in 
children and adolescents, with an incidence of approximately 50% of all soft tissue sarcomas in this 
age group [1,2]. In adult patients RMS is an orphan disease, accounting for only 3% of all soft 
tissue sarcomas [1-3]. There are different subtypes of RMS: pleomorphic, embryonal, alveolar 
(ARMS), and the botryoid and spindle cell variants [1,2,4]. Microscopically, ARMS consists of 
small densely packed round cells that resemble pulmonary alveoli, although a more solid variant 
has also been identified [1,2,5].  
 
In ARMS, specific chromosomal translocations occur in 70-80% of patients [2,6]. The disease is 
typically characterized by a fusion of the paired box 3 (PAX3) or PAX7 gene with forkhead box O1 
(FOXO1) [1,7]. In approximately 60% of ARMS, translocation t(2;13)(q35;q14) occurs; while in 
about 20% of ARMS translocation t(1;13)(p36;q14) is found [1,2]. The t(2;13)(q35;q14) 
translocation results in the expression of its chimeric transcription factors PAX3-FOXO1, while the 
t(1;13)(p36;q14) translocation results in the expression of PAX7-FOXO1 [1,2]. Both fusion genes 
encode the subsequent chimeric proteins, which are more abundant and transcriptionally more 
potent than their wild type counterparts [8-11]. Studies suggest that the presence of the PAX3-
FOXO1 and PAX7-FOXO1 fusion proteins downstream contribute towards tumourigenesis [8,11]. 
PAX-FOXO1 stimulates tumour cell proliferation, angiogenesis, activates the myogenic program 
and inhibits apoptosis [2,12]. PAX3 is a main regulator of myogenesis while PAX7 induces satellite 
cell specification [1,13,14]. 
 
PAX3 activates the transcription of a number of target genes, involved in myogenic cells lineage, 
including MET, MYOD (myogenic differentiation 1), and LBX1 (ladybird homeobox 1), and was 
shown to cause ligand-independent activation of MET in preclinical models [1,15-17]. MET 
encodes for the MET tyrosine kinase cell surface receptor, which is activated by its ligand 
hepatocyte growth factor (HGF), and MET phosphorylation in turn stimulates multiple signal 
pathways that play an important role in cell survival, proliferation, angiogenesis, migration, 
invasiveness, and metastasis [19-21]. The ARMS-specific PAX3-FOXO1 fusion leads to MET 
overexpression, frequently observed in this entity [1]. Although, Rees et al assessed the role of a 
putative hepatocyte growth factor (HGF)–MET pathway in in a panel of 68 clinical primary RMS 
samples and found MET was surprisingly a consistent feature of embryonal and not alveolar RMS 
[18]. 
 
Anaplastic lymphoma kinase (ALK) can also be overexpressed in RMS [22,23]. Studies have 
yielded conflicting results regarding the correlation between ALK positive staining and 
PAX3/PAX7-FOXO1 fusion status, which are generally found to be independent events [22]. 
Aberrant ALK expression can result in phosphorylation of the ALK tyrosine kinase receptor and the 
subsequent abnormal activation of multiple downstream signalling cascades, including the Janus 
kinase (JAK)/signal transducer and activator of transcription (STAT), phosphatidylinositol-3 
kinase/AKT (PI3-K/AKT), and RAS/extracellular signal-regulated kinase (ERK) pathways, which 
are associated with increased cell proliferation, prolonged tumour cell survival and enhanced cell 
migration [24-26]. ALK expression is an independent negative prognostic factor in ARMS [22]. 
 
Aberrant MET and ALK expression may promote resistance to chemotherapy resulting in poorer 
treatment outcome [1,3,22]. The presence of both MET and ALK pathway alterations in ARMS 
supports the assessment of crizotinib in this disease, as the drug inhibits both targets.  
 
Crizotinib (Xalkori®, PF-02341066, Pfizer Inc.) is a small molecule tyrosine kinase inhibitor (TKI) 
targeting MET, ALK, ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) and RON (Recepteur 
d’Origine Nantais) [27-31]. Crizotinib interferes with the ALK/MET pathways by competitively 
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preventing adenosine triphosphate (ATP) from binding to the ALK and MET receptors, therefore 
abrogating their phosphorylation [27-31]. This blocks the downstream cascade of events, thereby 
inhibiting the growth and survival of ALK or MET dependent cells [27-34]. Crizotinib is approved 
for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours are 
either ALK or ROS1 positive, and the recommended oral dose in adult patients is 250mg twice daily 
[29,30]. 
 
The European Organization for Research and Treatment of Cancer (EORTC) initiated a 
multinational, multi-tumour, prospective phase 2 clinical trial (EORTC 90101 “CREATE”) to 
evaluate the efficacy and safety of crizotinib in patients with advanced tumours driven by MET 
and/or ALK alterations. CREATE included 6 disease-specific cohorts, and we report here the 
results of the independent ARMS cohort. 
 
 




This was a multicentre, single agent, non-randomized, open-label, two-stage phase 2 trial, assessing 
crizotinib in patients with locally advanced/ metastatic ARMS. The patient population was divided 
by protocol into MET/ALK altered and MET/ALK non-altered sub-cohorts, which were analysed 
separately.  
 
Ethics approval was obtained for this study(ClinicalTrials.gov identifier NCT01524926), which was 
conducted in accordance with the Declaration of Helsinki, International Conference on 




Patient enrolment was based on a multi-step registration procedure. Step 1 prerequisites for 
registration were a local diagnosis of advanced ARMS deemed incurable by conventional surgery, 
radiotherapy or systemic therapy. Prior treatment with chemotherapy, the availability of a formalin-
fixed paraffin embedded (FFPE) tumour-containing tissue block from primary tumour and/or 
metastatic site for trial purposes, and written informed consent of the patient for central collection 
of the tissue and all other trial-specific procedures were mandatory inclusion criteria for ARMS 
patients. 
 
Criteria for step 2 included receipt of the tissue by a central biorepository (BioRep, Milan, Italy) 
with presence of tumour in the shipped material and confirmation of the correct diagnosis of ARMS 
by central reference pathology. 
 
Screened patients were treated after completion of both steps, provided all other eligibility criteria 




Documentation of the presence of a specific rearrangement leading to MET and/or ALK alteration 
was not required for a patient to enter the treatment phase (step 3). FISH analysis was done while 
patients were already receiving therapy, to avoid delaying the start of treatment for patients in need 




Treatment, safety and efficacy assessment 
 
Eligible patients with centrally confirmed diagnosis of ARMS were treated with oral crizotinib at a 
starting dose of 250 mg twice daily. One treatment cycle was defined as 21 days in duration. 
Treatment was continued until documented disease progression, unacceptable toxicity, or patient 
refusal. Treatment dose and schedule modifications were defined in the protocol.  
 
Safety information was collected at baseline, day 15 of cycle 1 and 2, and at the end of every cycle 
applying the Common Terminology Criteria for Adverse Events [CTCAE] version 4.0. Tumour 
assessments were performed every other cycle by the local investigator or radiologist according to 
RECIST 1.1 using computed tomography or magnetic resonance imaging. Objective responses were 
centrally reviewed. 
 
Assessment of MET/ALK alterations in archival tumour tissue 
 
Patients were attributed to MET/ALK altered or MET/ALK non-altered sub-cohorts on the basis of 
the presence or absence of a rearrangement of either FOXO1 (synonym: FHKR) upregulation (as a 
surrogate of MET) and/or ALK in archival tumour tissue, using commercial fluorescence break apart 
probe sets (Vysis® LSI® FKHR (13q14) Dual Colour Break Apart Rearrangement Probe; and 
Vysis® LSI® ALK Dual Colour Break Apart Rearrangement Probe, both from Abbott Molecular). 
The archival tissue originated from either the primary tumour or a metastatic lesion. The FISH 
analysis was done at the University Hospitals Leuven, Leuven (Belgium) using unstained 4µm 
slides. The protocol required at least 15% of cells with re-arrangement for a positive test results. At 
least FOXO1 or ALK had to be rearranged according to these criteria to define the tumour of a 




The main objective was to study the activity of crizotinib in ARMS patients with activated 
MET/ALK signalling. The primary endpoint was the ORR per RECIST 1.1 with response 
confirmation, assessed by the local investigator. This endpoint was chosen based on response 
pattern seen with crizotinib in the labelled indication of NSCLC and due to the relative absence of 
reliable reference data on PFS or PFR in adult patients with chemotherapy-refractory ARMS. 
Secondary endpoints included DOR, DCR, PFS, PFR, OS, safety, and correlative/translational 
research endpoints. DCR was defined as the percentage of patients achieving a complete (CR) or 




A Simon's optimal two-stage design was implemented with the aim of excluding an ORR ≤10% 
under the alternative assumption that 30% ORR can be achieved with crizotinib in MET/ALK 
rearranged disease. The type I error and power were set at 10%. The study was conceptually 
focused on this genetically defined sub-cohort, while patients with MET/ALK non-altered tumours 
were supposed to serve as a non-randomized, treated internal control. The entry of “all comers” 
independent of their MET/ALK status avoided delaying treatment for patients in need of an active 
intervention, given the progression dynamics of chemotherapy-resistant ARMS, and to provide 
reference data for both subsets for future clinical trials. The entry of MET/ALK negative cases was 
considered ethical due to the lack of validated treatment alternatives for this disease after failure of 
chemotherapy. We expected the vast majority of cases to have a rearrangement of FOXO1 and thus, 
using the FOXO1 rearrangement as a surrogate, these patients were categorised as MET positive. 
 
7 
In stage 1, if at least two out of the first 12 eligible and evaluable MET/ALK altered ARMS patients 
achieved a confirmed RECIST PR or CR, a maximum of 35 patients were to be enrolled. In stage 2, 
if <6 out of the 35 eligible and evaluable patients responded, the treatment was declared ineffective. 
If ≥6 out of the 35 patients responded, further study of crizotinib was warranted.  
 
Stopping rules and activity endpoints details are provided in the protocol. Analyses were performed 





Patient disposition, reference pathology, clinical screening and enrolment 
 
Between April 12, 2013 and November 4, 2016, 9 sites in 5 European countries recruited 20 
patients with the local diagnosis of ARMS. Nineteen (95.0%) of these 20 patients had centrally 
confirmed ARMS. The non-confirmed, non-eligible case had no tissue available for reference 
pathology and could not be included, and did not enter the screening or treatment phase of the trial.  
 
Thirteen of the 19 patients with centrally confirmed ARMS started treatment with crizotinib. 
Reasons for not entering the treatment phase in the 6 remaining patients were ineligibility (n=2), 
patient withdrawal (n=2) and rapid progression prior to study entry (n=2). Only 8 eligible patients 
with confirmed ARMS were evaluable for the primary and secondary endpoints of this trial due to 




FISH analysis was completed within a median time of 5 days (range: 1-13 days) after receipt of 
technically useful slides from the central biorepository. Among the 19 patients with centrally 
confirmed diagnosis, 18 (94.7%) had a FOXO1 gene rearrangement, and none of them had an ALK 
gene rearrangement detected using the validated FISH probes. These patients were grouped together 
according to protocol as the FOXO/ALK rearranged subset (MET+/ALK-). Only one patient (5.3%) 
had no detectable FOXO1 or ALK rearrangement (MET-/ALK-). An overview on all relevant genetic 
findings and treatment outcome per patient is shown in table 1.  
 
Recruitment to both the MET+/ALK- and MET-/ALK- sub-cohorts was suspended early on 
November 4, 2016 due a high rate of early radiological and/or clinical progression on the 
experimental treatment, a decision endorsed by the trial steering committee and the EORTC 




Among the total group of 19 patients with confirmed ARMS, 12 patients with MET+/ALK- disease 
and one patient with MET-/ALK- disease entered the treatment phase. Characteristics of the 13 
treated patients are shown in table 2. One paediatric patient was included. The median age was 30.0 
years (range: 6.0-48.0), 38.5% (5/13) had an ECOG PS of 1, all patients (13/13) had received prior 
chemotherapy and 38.5% (5/13) had undergone prior major surgery. The majority of patients had 
received at least three prior lines of therapy and 15% had previously undergone high-dose 





As of September 11, 2017, with a median follow-up of 154 days (range: 21-212), all patients have 
stopped receiving treatment. The mean relative dose intensity was 97.7%. None of the patients had 
dose reductions or dose modifications, but one patient interrupted crizotinib due to haematological 
adverse events. Total treatment duration with crizotinib ranged from 7-103 days, with a very short 
median duration of 22 days and a median number of treatment cycles of only 1 (range: 1-5) in the 
MET+/ALK- sub-cohort. All 13 patients came off study due to disease progression. This included 5 
patients with symptomatic deterioration who according to local investigator did not qualify for 
radiological confirmation of disease progression due the aggressiveness of the underlying 
malignancy.  
 
Activity of crizotinib 
 
Among the 13 eligible and treated patients, 8 were evaluable with at least one RECIST assessment 
after treatment start. A single, short lasting, confirmed partial response was observed in one of 7 
evaluable MET+/ALK- patients (14.3% ORR; 95% confidence interval (CI): 0.3-57.8%; DOR: 52 
days). The single evaluable MET-/ALK- patient did not achieve an objective response. Key efficacy 
data are summarized in table 3. 
 
None of the remaining eligible and evaluable patients in this trial achieved RECIST SD. Disease 
progression was the best response in 6 out of 7 MET+/ALK- patients (85.7%). The MET-/ALK- 
patient had disease progression at the first on treatment assessment. 
 
Median PFS was 1.3 months (95% CI: 0.5-1.5) in MET+/ALK- cases. All patients progressed within 
4 months after treatment start. The Kaplan-Meier estimates for PFS are shown in figure 2A. Median 
OS was 5.6 months (95% CI: 0.7-7.0) in MET+/ALK- cases and the OSR at 6 months was only 
28.6% (95% CI: 4.1-61.2%). The Kaplan-Meier estimates for OS are shown in figure 2B.  All 
patients entering the treatment phase of this trial died early due to progression of ARMS. 
 
Figure 2C illustrates the maximum target lesion shrinkage, figure 2D summarizes the poor clinical 
course of the treated patients. 
 
Safety and toxicity 
 
No new or unexpected safety signals for crizotinib were detected in the ARMS patients. The most 
common treatment-related adverse events were fatigue (38.5% of patients), nausea (30.8%), 
anorexia (30.8%), vomiting (15.4%) and constipation (15.4%). The reported treatment-related grade 
3 adverse events were fatigue (2 patients), no grade 4 events were observed. Adverse events details 
are shown in Tables 4A and 4B.  
 
Serious adverse events included a systemic inflammatory response syndrome (1 patient), respiratory 
infection (1 patient), dehydration (1 patient) and chest pain (1 patient). Only the first event was 
considered possibly related to study treatment. 
 
A total number of 5 deaths occurred on treatment or within 4 weeks of treatment discontinuation, 
but none of them was treatment related.  
 
 
Discussion   
 
Alveolar rhabdomyosarcoma belongs to the expanding group of sarcomas characterized by fusions 
of the PAX3 or PAX7 gene with FOXO1 [1,2,6,7]. PAX3 activates the transcription of a number of 
target genes, including MET [1,15-17]. The MET receptor is significantly overexpressed in ARMS 
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[1]. In addition to MET and likely unrelated to the PAX3/PAX3-FOXO1 fusion status, ALK can be 
overexpressed in RMS [22].  
 
The theoretical presence of both MET and ALK pathway alterations in ARMS provided a strong 
rationale to test the MET, ALK and ROS1 TKI crizotinib in this disease. Preclinical studies have 
shown that crizotinib can block the downstream cascade of events as described above [26,29], 
thereby inhibiting the growth and survival of ALK or MET dependent cells, which translates into 
impressive anti-tumour effects of the compound in the labelled indication of NSCLC [29]. 
 
We were not able to demonstrate clinically meaningful activity of crizotinib in adult patients with 
chemotherapy-refractory ARMS. Only one patient had a short objective response. A striking 
finding was that none of our non-responding patients achieved disease stabilization according to 
RECIST, which underscores the clinical aggressiveness of the disease. To this end, some patients 
could not even enter the study due to rapid progression during trial screening; many others had 
early disease progression on crizotinib preventing further imaging assessments, and all died within 
less than 6 months after study entry due to progressive ARMS. This made a significant proportion 
of our study population non-evaluable for the primary endpoint, which led to the ethical decision by 
the Steering Committee to discontinue recruitment of further patients to this arm of EORTC 90101 
“CREATE”, before having reached the critical number 12 eligible ARMS patients with gene 
alterations evaluable for response. Only 7 MET+/ALK- patients were evaluable for response, after 
recruitment of 19 patients with documented diagnosis of ARMS.  
 
The poor outcome of crizotinib treatment in rhabdomyosarcoma observed in our study is similar to 
findings in other recent clinical trial, e.g. a phase 2 study by Schuetze et al with dasatinib where 
only 1/13 patients achieved stable disease with a median PFS of 0.9 months [35], and a phase 2 trial 
by Pappo et al with R1507 (a monoclonal antibody to the insulin-like growth factor-1 receptor ) that 
achieved 1 PR, 3 unconfirmed PR and median PFS of 5.6 weeks in 36 enrolled patients [36]. The 
results of these trials support the conclusion that previously treated RMS is a rapidly progressive, 
aggressive cancer and new trial designs are needed to test novel agents in this disease. 
 
While FOXO1 alterations were present in all but one centrally confirmed ARMS case in our trial, 
no patient had an ALK gene rearrangement based on the use of a validated commercial FISH probe. 
We did not perform additional immunohistochemistry for ALK or other tests in the available tissue 
samples, since we believe that ALK may not be a relevant target in our series in the absence of a 
genetic event and the reported overexpression of ALK in ARMS is rather a passenger effect [37]. 
While expression of MET was not tested in this cohort of patients we assume that based on the lack 
of clinical benefit in this patient cohort, any MET activation would play a minor role in driving the 
disease. PAX3 had been shown to activate MET during muscle development thus it may be more 
relevant for lineage-specific differentiation than as pro-survival pathway [18]. Pandey et al recently 
published that upon recurrence, tumor cells gain increasing independence from the PAX3-FOXO1 
mechanism [38]. This supports the need for fresh biopsies in clinical trials with targeted agents. 
 
A recent integrated genetic and epigenetic analysis on RMS revealed that 32% of patients had 
genomic dysregulation of signalling intermediates activating the RAS/RAF and the PI3-K pathway 
[39]. While these genes have not been sequenced in our study they are known to confer resistance 
to kinase inhibitors.  
 
Based on our observations, heavily pre-treated ARMS represent a subgroup of patients with a 
particularly aggressive disease and poor prognosis. The high risk of losing patients quickly while on 
a single, targeted drug suggests it would be better to test novel therapies as an earlier treatment line 
[40], preferably in combination with chemotherapy – unless the genomic marker is more predictive. 
Chemotherapy can also influence expression levels of RTKs, which possibly provides another 
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reason to test targeted therapy in earlier lines of treatment. In theory it could be more accurate to 
test post-chemotherapy resection specimens for target expression levels, although repetitive 
sampling in such patients may be challenging, especially in symptomatic patients with rapidly 
progressive disease. An alternative approach would be to test novel targeted agents in the context of 
ongoing or planned RMS trials, randomizing patients to conventional chemotherapy +/- novel 
agent. This concept has a long tradition mainly in paediatric sarcoma trials, and may also apply 
here. 
 
The investigators of EORTC 90101 only entered one paediatric patient with ARMS. Our efficacy 
findings cannot be extrapolated to younger patients with other subtypes of rhabdomyosarcoma, 
nevertheless our data are consistent with those from a clinical trial of ceritinib in paediatric patients 
including ARMS [41].  
 
In summary, crizotinib is well tolerated but does not have clinically relevant activity as a single 
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Table 1. Molecular characteristics of centrally confirmed alveolar rhabdomyosarcomas in this trial 
and their response to crizotinib.  






























MET+/ALK- patients          
47 Metastatic 87 0 Stopped 5 91 PR Death 173 
50 Metastatic 15 0 Stopped 2 42 PD Death 260 
83 Primary 75 2 Stopped 1 22 Missing Death 34 
100 Primary 91 0 Not treated - - - - - 
102 Metastatic 81 0 Stopped 1 13 Missing Death 16 
104 Primary 77 0 Stopped 1 22 PD Death 41 
111 Primary 93 0 Stopped 1 21 Missing Death 62 
119 Primary 73 0 Not treated - - - - - 
130 Primary 76 0 Stopped 2 44 PD Death 170 
136 Metastatic 74 0 Stopped 2 29 PD Death 101 
152 - 48 0 Not treated - - - - - 
162 Primary 27 0 Stopped 1 13 Missing Death 44 
174 Primary 79 0 Stopped 2 41 PD Death 212 
179 Primary 95 0 Stopped 1 8 Missing Death 14 
181 Primary 84 4 Stopped 1 PD PD Death 21 
183 Primary 95 0 Not treated - - - - - 
184 Primary 85 0 Not treated - - - - - 
187 Metastatic 95 0 Not treated - - - - - 
          
MET-/ALK- patient          
11 Primary 0 0 Stopped 2 38 PD Death 138 
Legend: Missing, clinical progression without radiological confirmation; PD, progressive disease; 
RECIST, Response Evaluation Criteria in Solid Tumours 
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Table 2. Key patient characteristics.  
 







Age (years)                                                                                                                                                                                                        
     Median                                                                                                                                                                                                  28.5 32.0               30.0
     Range                                                                                                                                                                                                   16.0 - 48.0 32.0 - 32.0 16.0 - 48.0        
Eastern Cooperative Oncology Group performance status     
    0                                                                                                    1 (8.3%)                                                                                          1 (100.0%)                                        2 (15.4%)                                         
    1                                                                                                    5 (41.7%)                                                                                         0 (0.0%)                                     5 (38.5%)                                           
    2     6 (50.0%)                                                                                         0 (0.0%)                                       6 (46.2%)                                                       
Sex                                                                                                  
    Male                                                                                                11 (91.7%)                                                                                         0 (0.0%)                                    11 (84.6%)                                            
    Female                                                                                               1 (8.3%)                                                                                          1 (100.0%)                                        2 (15.4%)                                         
Any previous major surgery        4 (33.3%)                                                                                         1 (100.0%)                                       5 (38.5%)                                         
Any prior systemic anticancer therapy    12 (100.0%)                                                                                        1 (100.0%)                                      13 (100.0%)                                           
    Chemotherapy    12 (100.0%)                                                                                        1 (100.0%)                                     13 (100.0%)                                           
    Autologous or allogenic stemcell or bone marrow transplant              2 (16.7%)                                                                                        0 (0.0%)                                      2 (15.4%)                                           
Prior systemic treatments    
    Neo-adjuvant     1 (8.3%)                                                                                          1 (100.0%)                                        2 (15.4%)                                         
    Adjuvant     3 (25.0%)                                                                                         1 (100.0%)                                       4 (30.8%)                                         
    Maintenance     4 (33.3%)                                                                                         0 (0.0%)                                     4 (30.8%)                                           
    1st line    12 (100.0%)                                                                                        0 (0.0%)                                    12 (92.3%)                                                         
    2nd line    11 (91.7%)                                                                                         0 (0.0%)                                    11 (84.6%)                                            
    3rd line     9 (75.0%)                                                                                         0 (0.0%)                                     9 (69.2%)                                           
    4th line     4 (33.3%)                                                                                         0 (0.0%)                                     4 (30.8%)                                           
    5th line     1 (8.3%)                                                                                          0 (0.0%)                                        1 (7.7%)                                                       




Table 3. Response assessment and efficacy summary, according to investigator assessment. 
 











Best RECIST 1.1 response                                                                                                                                                                           
       Partial response           1 (14.3%)                                                                                         0 (0.0%)                                   1 (12.5%)                                    
       Progressive disease                       6 (85.7%)                                                                                         1 (100.0%)                                     7 (87.5%)                                  
    
Objective Response rate               14.3% 0% 12.5% 
       (95% CI) (0.3 -57.8) (-) (0.3-52.6) 
Disease control rate 14.3% 0% 12.5% 
       (95% CI) (0.3 -57.8) (-) (0.3-52.6) 
    
Progression-free survival                          
       Progression of ARMS or died                                            7 (100.0%)                                                                                        1 (100.0%)                                    8 (100.0%)                                   
       6-months progression-free survival rate 0.0%  0.0%  0.0%            
       (95% CI) (-)           (-)           (-)           
    
Survival status        
       Dead               7 (100.0)                                                                                        1 (100.0%)                                       8 (100.0%)                                   
       Reason of death                                 
           Progression of ARMS                             7 (100.0)                                                                                        1 (100.0%)                                       8 (100.0%)                                   
       6-months survival rate  28.6% 0.0% 25.0% 
       (95% CI) (4.1, 61.2) (-)           (3.7, 55.8)          
Legend: CI, confidence interval 
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Figure 2A. Kaplan-Meier estimates for progression-free survival for the MET+/ALK- and MET-




Figure 2B. Kaplan-Meier estimates for overall survival for the MET+/ALK- and MET-/ALK- sub-
cohorts per protocol. 
 
Legend: The vertical bar represent the 95% confidence interval (CI), for the 6 month estimate of the 
overall survival rate.  
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Figure 2C. Maximum shrinkage of target lesions (per protocol) in the MET+/ALK- and MET-/ALK- 
sub-cohorts, according to local investigator’s assessment. 
 









Table 4. Non-haematological adverse events that occurred in  10% of patients. 
 
All adverse events 
Present in ≥10% of patients 
(Safety population, N=13) 
Treatment-related adverse events 
Present in ≥10% of patients 
(Safety population, N=13) 
CTC + MedDRA Term 
Gr 1      
N (%) 
Gr 2      
N (%) 
Gr 3      
N (%) 
Gr 4     
N (%) 
Gr ≥3     
N (%) 
All grades     
 N (%) 
 Gr 1      
N (%) 
  Gr 2      
N (%) 
 Gr 3      
N (%) 
Gr 4     
N (%) 
Gr ≥3     
N (%) 
All grades     
N (%) 
NUMBER OF PATIENTS WITH 
AE's 
2 (15.4) 5 (38.5) 4 (30.8) 2(15.4) 6 (46.2) 13 (100.0) 2 (15.4) 2 (15.4) 3 (23.1)  3 (23.1) 7 (53.8) 
GASTROINTESTINAL 
DISORDERS 
            
    Constipation 3 (23.1) 3 (23.1)    6 (46.2) 1 (7.7) 1 (7.7)    2 (15.4) 
    Diarrhoea 3 (23.1)         3 (23.1)       
    Nausea 4 (30.8) 4 (30.8)    8 (61.5) 1 (7.7) 3 (23.1)    4 (30.8) 
    Vomiting 4 (30.8)     4 (30.8) 2 (15.4)     2 (15.4) 
GENERAL DISORDERS AND 
ADMINISTRATION SITE 
CONDITIONS 
            
    Fatigue 1 (7.7) 3 (23.1) 3 (23.1)  3 (23.1) 7 (53.8) 1 (7.7) 2 (15.4) 2 (15.4)  2 (15.4) 5 (38.5) 
    Fever 2 (15.4)         2 (15.4)       
    Pain 1 (7.7) 1 (7.7)    2 (15.4)       
    Other AE 1 (7.7)  3 (23.1)  3 (23.1) 4 (30.8)       
INVESTIGATIONS             
    Weight loss 2 (15.4)         2 (15.4)       
METABOLISM AND NUTRITION 
DISORDERS 
            
    Anorexia 2 (15.4) 3 (23.1)       5 (38.5) 2 (15.4) 2 (15.4)       4 (30.8) 
    Dehydration 1 (7.7)  1 (7.7)  1 (7.7) 2 (15.4)       
NEOPLASMS BENIGN, 
MALIGNANT AND 
UNSPECIFIED (INCL. CYSTS 
AND POLYPS) 
 
            
    Tumour Pain  2 (15.4)    2 (15.4)       
RENAL AND URINARY 
DISORDERS 
 
            
    Other AE 1 (7.7)   1 (7.7)   1 (7.7) 2 (15.4)       
RESPIRATORY THORACIC AND 
MEDIASTINAL DISORDERS 
            
    Dyspnoea 1 (7.7) 4 (30.8)       5 (38.5)       
    Pleural Effusion  1 (7.7) 1 (7.7)  1 (7.7) 2 (15.4)       
SK SUBCUTANEOUS TISSUE 
DISORDERS 
            
    Alopecia 1 (7.7) 1 (7.7)       2 (15.4)       
Legend: AE, Adverse event; Gr: Grade; CTC, Common Terminology Criteria   
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Table 5. Haematological and biochemical adverse events that occurred in  10% of patients. 
 
      
 Grade1 Grade2 Grade3 Grade4 N (%) 
Alkaline phosphatase   3 1   4 (30.8) 
Anaemia  2 1  3 (23.1) 
SGPT  2  1  3 (23.1) 
Hypocalcaemia  1 1 1  3 (23.1) 
Serum creatinine   4 1   5 (38.5) 
Hyperglycaemia   2 1   3 (23.1) 
Hyperkalaemia   2    2 (15.4) 
Hyponatremia   2  3  5 (38.5) 
Legend: Treatment emergent effects. Relationship not collected for these laboratory events; SGPT, 
serum glutamic-pyruvic transaminase.  
